Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases—A Synthetic Review

Abstract

Dermatological diseases pose a significant burden on the quality of life of individuals and can be challenging to treat effectively. In this aspect, cannabinoids are gaining increasing importance due to their therapeutic potential in various disease entities including skin diseases. In this synthetic review, we comprehensively analyzed the existing literature in the field of potential dermatological applications of a lesser-known subgroup of cannabinoids, the so-called minor cannabinoids, such as cannabidivarin (CBDV), cannabidiforol (CBDP), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabielsoin (CBE), cannabimovone (CBM) or cannabinol (CBN), while drawing attention to their unique pharmacological properties. We systematically searched the available databases for relevant studies and analyzed the data to provide an overview of current thematic knowledge. We looked through the full-text, bibliographic and factographic databases, especially Scopus, Web of Science, PubMed, Polish Scientific Journals Database, and selected the most relevant papers. Our review highlights that minor cannabinoids exhibit diverse pharmacological activities, including anti-inflammatory, analgesic, antimicrobial, and anti-itch properties. Several studies have reported their efficacy in mitigating symptoms associated with dermatological diseases such as psoriasis, eczema, acne, and pruritus. Furthermore, minor cannabinoids have shown potential in regulating sebum production, a crucial factor in acne pathogenesis. The findings of this review suggest that minor cannabinoids hold therapeutic promise in the management of dermatological diseases. Further preclinical and clinical investigations are warranted to elucidate their mechanisms of action, determine optimal dosage regimens, and assess long-term safety profiles. Incorporating minor cannabinoids into dermatological therapies could potentially offer novel treatment options of patients and improve their overall well-being.

Effect of High-Tunnel and Open-Field Production on the Yield, Cannabinoids, and Volatile Profiles in Industrial Hemp (Cannabis sativa L.) Inflorescence

“…Among the parts of industrial hemp, the hemp flower has garnered global attention due to the plethora of bioactive compounds with superior nutraceutical and therapeutic values. For instance, cannabidiol (CBD) possesses several biological activities, including antimicrobial, antioxidant, anti-inflammatory, anticancer, and antiarthritic properties, reduces stress and anxiety, relieves pain, and promotes relaxation. , Cannabigerol (CBG) is a minor cannabinoid showing positive effect on chronic pain, depression, inflammatory bowel disease, bacterial infections, and cancer. , Similarly, cannabichromene (CBC) holds potential therapeutic benefits, such as anti-inflammatory and antinociceptive properties, and improves respiratory distress syndrome. − Furthermore, binary cannabinoid mixtures containing combinations of neutral and acidic cannabinoids (e.g., cannabidiol (CBD) together with cannabidiolic acid (CBDA)) display superior synergistic antioxidant effects compared to their potential as individual compounds . CBD, CBG, and CBC fall under nonpsychoactive cannabinoids, making them suitable for future food, pharmaceutical, and medicinal applications. , Meanwhile, industrial hemp also contains a psychoactive cannabinoid, delta-9-tetrahydrocannabinol (d9-THC).…”